Ibrolipim, Inhibitor

Ibrolipim

Cat. Num. AAA5758696

• Purity: 99.47%
• Synonyms: Ibrolipim; NO-1886; inhibitor

• Purity/Purification: 99.47%
• Form/Format: Solid. Powder

• Solubility: DMSO: 125mg/mL (277.01mM) Need ultrasonic; (<1mg/ml refers to the product slightly soluble or insoluble)
• Formula: Br1C19H20N2O4P1
• SMILES: CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC
• CAS Number: 133208-93-2
• Target & IC50: Lipoprotein lipase (LPL)
• Cell Research: Human THP-1 cells pre-incubated with ox-LDL served as foam cell models. Specific mRNA was quantified using real-time RT-PCR and protein expression using Western blotting. Cellular cholesterol handling was studied using cholesterol efflux experiments and high performance liquid chromatography assays[1]
• In Vitro: Ibrolipim (NO-1886; 100mg/kg; oral administration; daily; for 8 weeks; female Sprague-Dawley rats) treatment,decreases accumulation of visceral fat and suppresses the increase in body weight resulting from the ovariectomy. Ibrolipim decreases the respiratory quotient and increases expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. Ibrolipim also increases the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue[2]
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Structure

Related Product Information for Ibrolipim, inhibitor

Ibrolipim attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway.

References

Chen SG, et al. Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31(10):1343-9.
Chen SG, et al. Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31(10):1343-9.
Kano S, Doi M. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats[J]. Metabolism-clinical & Experimental, 2006, 55(2):151-158.
Kano S, Doi M. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats[J]. Metabolism-clinical & Experimental, 2006, 55(2):151-158.
Chen SG, Xiao J, Liu XH,et al.Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31(10):1343-9.